Idorsia successfully completes an upsized offering of shares funding the company to overall profitability
Ad hoc announcement pursuant to Art. 53 LR NOT FOR RELEASE, PUBLICATION,…
Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025
NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX),…
Persistent Achieves Top Rankings for the Second Year in a Row in Extel’s Asia Executive Team Survey
Recognized under multiple categories, including Best CEO, Company Board of Directors, Overall…
